基于心-肠轴的参芍片干预慢性心力衰竭机制研究

贾秋瑾 ,  范鹿 ,  张浩敏 ,  王小玲 ,  张晓囡 ,  袁鹏 ,  郝玉杰 ,  韩文宝 ,  袁卓 ,  王云姣 ,  赵超 ,  吕仕超

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1310 -1319.

PDF (5988KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1310 -1319. DOI: 10.12092/j.issn.1009-2501.2026.10.002
基础研究

基于心-肠轴的参芍片干预慢性心力衰竭机制研究

作者信息 +

Study on the mechanism of Shenshao tablets based on heart-intestinal flora axis in the treatment of chronic heart failure

Author information +
文章历史 +
PDF (6131K)

摘要

目的: 从肠道菌群角度探讨参芍片干预慢性心力衰竭的作用机制。方法: 采用异丙肾上腺素诱导慢性心力衰竭大鼠模型,随机分为对照组、模型组、参芍低/高剂量组(216/432 mg/kg)、人参茎叶皂苷组(18.72 mg/kg)及白芍总苷组(216 mg/kg)。干预 4 周后,检测心功能、心肌胶原沉积、肠屏障功能相关指标,并行 16S rDNA 测序与靶向代谢组学分析。结果: 与对照组相比,模型组大鼠心功能下降,心肌纤维化加重,肠屏障受损。参芍片干预后,心力衰竭大鼠左室舒张末期内径(left ventricular end diastolic dimension,LVEDD)、左室收缩末期内径(left ventricular end systolic diameter,LVESD)、N 端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-ProBNP)降低,左室射血分数(left ventricular ejection fraction,LVEF)升高(P<0.05 或P<0.01);心肌胶原沉积减少,血清二胺氧化酶(diamine oxidase,DAO)、D-乳酸和内毒素水平下降,肠黏膜结构改善(P<0.05 或P<0.01)。肠道菌群分析显示,心力衰竭大鼠 Melainabacteria 菌门和Paraprevotella 属丰度升高,Actinobacteria 门丰度降低,参芍片能够增加菌群多样性,促进有益菌富集,降低 Spirochaetes 门丰度,同时降低血清氧化三甲胺水平并提高短链脂肪酸含量。结论: 参芍片能够改善慢性心力衰竭心肌重构与肠屏障功能,且整体效果优于单一成分,其心肌保护作用可能与调节肠道菌群结构及代谢产物相关,提示参芍片可能通过心-肠轴发挥心肌保护作用。

Abstract

AIM: To investigate the mechanism of Shenshao tablet in treating chronic heart failure (CHF) from the perspective of gut microbiota. METHODS: The CHF model of rat was established by isoproterenol and randomly divided into control, model, low-/high-dose Shenshao tablet, ginseng stem-leaf saponin, and total glucosides of paeony groups. After 4 weeks, cardiac function, myocardial collagen deposition, and intestinal barrier function were assessed. 16S rDNA sequencing and targeted metabolomics were performed. RESULTS: Compared with control group, there were decreased cardiac function, aggravated myocardial fibrosis, and impaired intestinal barrier in the model group. Shenshao tablet reduced LVEDD, LVESD, and NT-proBNP levels, increased LVEF, decreased myocardial collagen deposition, and lowered serum levels of DAO, D-lactate, and endotoxin. Gut microbiota analysis revealed increased abundances of Melainabacteria phylum and Paraprevotella genus, and decreased Actinobacteria phylum in HF rats. Shenshao tablet increased microbial diversity, enriched beneficial bacteria, reduced Spirochaetes phylum abundance, lowered serum trimethylamine N-oxide, and elevated short-chain fatty acids. CONCLUSION: Shenshao tablet ameliorates myocardial remodeling and intestinal barrier dysfunction in chronic heart failure, with effects superior to its individual components. Its cardioprotective mechanism may be associated with the regulation of gut microbiota structure and metabolites.

关键词

参芍片 / 肠道菌群 / 氧化三甲胺

Key words

Shenshao tablets / gut microbiota / trimethylamine N-oxide

引用本文

引用格式 ▾
贾秋瑾,范鹿,张浩敏,王小玲,张晓囡,袁鹏,郝玉杰,韩文宝,袁卓,王云姣,赵超,吕仕超. 基于心-肠轴的参芍片干预慢性心力衰竭机制研究[J]. 中国临床药理学与治疗学, 2026, 31(10): 1310-1319 DOI:10.12092/j.issn.1009-2501.2026.10.002

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

中国老年医学学会心电与心功能分会, 中国心衰中心联盟专家委员会, 中华医学会《中华全科医师杂志》编辑委员会. 心力衰竭早期筛查与一级预防中国专家共识 (2024 年)[J].中华全科医师杂志, 2024, 23(1): 7-18.

[2]

心血管健康联盟, 中国老年医学学会心电与心功能分会, 心衰中心联盟专家委员会. 中国心衰中心联盟心力衰竭医疗质量报告 (2022 年)[J].中华全科医师杂志, 2023, 22(6): 557-568.

[3]

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation, 2022, 145(18): e895-e1032.

[4]

刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告 2023》概要 (心血管疾病流行及介入诊疗状况)[J].中国介入心脏病学杂志, 2024, 32(10): 541-550.

[5]

Chen Y, Zhou J, Wang L.Role and mechanism of gut microbiota in human disease[J].Front Cell Infect Microbiol, 2021, 11: 625913.

[6]

Pasini E, Aquilani R, Testa C, et al. Pathogenic gut flora in patients with chronic heart failure[J].JACC Heart Fail, 2016, 4(3): 220-227.

[7]

Nagatomo Y, Tang WH.Intersections between microbiome and heart failure: revisiting the gut hypothesis[J].J Card Fail, 2015, 21(12): 973-980.

[8]

Sun H, Xing ZY, Huang JY, et al. Meta-analysis and trial sequential analysis of Shenshao Capsules in treatment of angina pectoris in coronary heart disease[J].China J Chin Mater Med, 2024, 49(12): 3385-3395.

[9]

刘云霏. 参芍片对冠心病合并心衰患者心功能及生活质量的影响[J].慢性病学杂志, 2020, 21(2): 228-229,232.

[10]

Xie B, Zu X, Wang Z, et al. Ginsenoside Rc ameliorated atherosclerosis via regulating gut microbiota and fecal metabolites[J].Front Pharmacol, 2022, 13: 990476.

[11]

Yang X, Dong B, An L, et al. Ginsenoside Rb1 ameliorates glycemic disorder in mice with high fat diet-induced obesity via regulating gut microbiota and amino acid metabolism[J].Front Pharmacol, 2021, 12: 756491.

[12]

Xu SY, Cao HY, Yang RH, et al. Genus Paeonia monoterpene glycosides: a systematic review on their pharmacological activities and molecular mechanisms[J].Phytomedicine, 2024, 127: 155483.

[13]

Zhan Y, Wen Y, Zhang LL, et al. Paeoniflorin improved constipation in the loperamide-induced rat model via TGR5/TRPA1 signaling-mediated 5-Hydroxytryptamine secretion[J].Evid Based Complement Alternat Med, 2021, 2021: 6076293.

[14]

Zhang Y, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China Heart Failure (China-HF) registry[J].J Card Fail, 2017, 23(12): 868-875.

[15]

Stewart S, MacIntyre K, Hole DJ, et al. More "malignant" than cancer? Five-year survival following a first admission for heart failure[J].Eur J Heart Fail, 2001, 3(3): 315-322.

[16]

Masenga SK, Povia JP, Lwiindi PC, et al. Recent advances in microbiota-associated metabolites in heart failure[J].Biomedicines, 2023, 11(8): 2313.

[17]

Dai H, Hou T, Wang Q, et al. Causal relationships between the gut microbiome, blood lipids, and heart failure: a Mendelian randomization analysis[J].Eur J Prev Cardiol, 2023, 30(12): 1274-1282.

[18]

Schneider E, O'Riordan KJ, Clarke G, et al. Feeding gut microbes to nourish the brain: unravelling the diet-microbiota-gut-brain axis[J].Nat Metab, 2024, 6(8): 1454-1478.

[19]

Sanchez-Gimenez R, Ahmed-Khodja W, Molina Y, et al. Gut microbiota-derived metabolites and cardiovascular disease risk: a systematic review of prospective cohort studies[J].Nutrients, 2022, 14(13): 2654.

[20]

Shen S, Tian B, Zhang H, et al. Heart failure and gut microbiota: what is cause and effect?[J].Research (Wash D C), 2025, 8: 0610.

[21]

Tang WHW, Lemaitre RN, Jensen PN, et al. Trimethylamine N-oxide and related gut microbe-derived metabolites and incident heart failure development in community-based populations[J].Circ Heart Fail, 2024, 17(8): e011569.

[22]

Yukino-Iwashita M, Nagatomo Y, Kawai A, et al. Short-chain fatty acids in gut-heart axis: their role in the pathology of heart failure[J].J Pers Med, 2022, 12(11): 1805.

[23]

Chulenbayeva L, Issilbayeva A, Sailybayeva A, et al. Short-chain fatty acids and their metabolic interactions in heart failure[J].Biomedicines, 2025, 13(2): 343.

[24]

Poland JC, Flynn CR.Bile acids, their receptors, and the gut microbiota[J].Physiology (Bethesda), 2021, 36(4): 235-245.

[25]

Wan S, Cui Z, Wu L, et al. Ginsenoside Rd promotes omentin secretion in adipose through TBK1-AMPK to improve mitochondrial biogenesis via WNT5A/Ca2+ pathways in heart failure[J].Redox Biol, 2023, 60: 102610.

[26]

Yu T, Xu X, Wei J, et al. Ginsenoside Rg5 alleviates Ang II-induced cardiac inflammation and remodeling by inhibiting the JNK/AP-1 pathway[J].Int Immunopharmacol, 2023, 120: 110408.

[27]

Peng Y, Liao B, Zhou Y, et al. Ginsenoside Rb2 improves heart failure by down-regulating miR-216a-5p to promote autophagy and inhibit apoptosis and oxidative stress[J].J Appl Biomed, 2023, 21(4): 180-192.

[28]

Zhu YL, Wang LY, Wang JX, et al. Protective effects of paeoniflorin and albiflorin on chemotherapy-induced myelosuppression in mice[J].Chin J Nat Med, 2016, 14(8): 599-606.

[29]

Luqman A, Hassan A, Ullah M, et al. Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder[J].Front Immunol, 2024, 15: 1321395.

[30]

Zhang Z, Wu G, Yang J, et al. Integrated network pharmacology, transcriptomics and metabolomics to explore the material basis and mechanism of Danggui-Baishao herb pair for treating hepatic fibrosis[J].J Ethnopharmacol, 2025, 337(Pt 1): 118834.

基金资助

天津市卫生计生行业高层次人才选拔培养工程(津人才〔2017〕18号)

AI Summary AI Mindmap
PDF (5988KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉